Cue Biopharma
90 hedge funds and large institutions have $186M invested in Cue Biopharma in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 26 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
1.86% less ownership
Funds ownership: 53.61% → 51.75% (-1.9%)
24% less capital invested
Capital invested by funds: $246M → $186M (-$59.8M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
90
Holding in Top 10
1
Calls
$1.48M
Puts
$1.11M
Top Buyers
| 1 | +$7.52M | |
| 2 | +$4.02M | |
| 3 | +$1.97M | |
| 4 |
BlackRock
New York
|
+$1.47M |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$1.24M |
Top Sellers
| 1 | -$13.8M | |
| 2 | -$10.8M | |
| 3 | -$4.15M | |
| 4 |
Morgan Stanley
New York
|
-$3.36M |
| 5 |
Goldman Sachs
New York
|
-$927K |